QIAGEN Advances NGS Efficiency with QIAseq Normalizer Kits for DNA Library Optimization

QIAGEN Advances NGS Efficiency with QIAseq Normalizer Kits for DNA Library Optimization

(IN BRIEF) QIAGEN has launched the QIAseq Normalizer Kits, a new solution for researchers to efficiently pool different DNA libraries for optimal results in next-generation sequencing (NGS) runs. The kit accelerates the process of normalizing DNA concentrations across libraries, reducing time and cost compared to traditional methods. It supports high-throughput applications, works without hazardous chemicals, and can be used with QIAGEN’s library prep solutions or other providers’ workflows for Illumina sequencing. The QIAseq Normalizer generates double-stranded DNA libraries, enhancing stability for long-term storage. This addition expands QIAGEN’s NGS portfolio, offering fast and efficient solutions for various genomics applications. QIAGEN’s bioinformatics capabilities and strategic partnerships further strengthen their position in the NGS field.

(PRESS RELEASE) VENLO, the Netherlands, 5-Jul-2023 — /EuropaWire/ — QIAGEN (NYSE: QGEN), a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, is pleased to announce the launch of the QIAseq Normalizer Kits, offering researchers a fast, convenient, and cost-effective method to combine different DNA libraries for optimal results in next-generation sequencing (NGS) runs.

The QIAseq Normalizer Kit significantly accelerates the process of equalizing DNA concentrations across NGS libraries, known as normalization, reducing the time required from several hours to just 30 minutes. It eliminates the need for time-consuming and expensive quantification procedures typically used for DNA libraries. The kit is designed for high-throughput applications, enabling parallel normalization of 96 samples, and is automation-friendly, operating without the use of hazardous chemicals.

“The QIAseq Normalizer’s big strength is its ability to reliably normalize all library types across a wide range of concentrations quickly and cheaply,” said Dr. Thomas Schweins, Senior Vice President and Head of QIAGEN’s Life Sciences Business Area. “Library pooling is the key to cost-effective, high-yield multiplexed sequencing – and QIAGEN’s normalization kit is crucial for ensuring researchers get consistent and high-quality sequencing data by minimizing any uneven representation of libraries.”

Researchers can seamlessly integrate the QIAseq Normalizer with QIAGEN’s existing QIAseq library prep solutions, streamlining their NGS workflows. It is also compatible with a range of DNA- and RNA-library prep workflows from other providers for Illumina sequencing platforms. The QIAseq Normalizer generates double-stranded DNA libraries, which offer improved stability and suitability for long-term storage compared to the single-stranded libraries produced by competing products.

This new kit further expands QIAGEN’s comprehensive next-generation sequencing portfolio, empowering researchers to unlock the full potential of NGS in biological research. By reducing turnaround times and maximizing sequencing capacity, QIAGEN delivers fast and efficient solutions. With a strong focus on front-end sample processing and downstream bioinformatics, QIAGEN offers innovative NGS technologies for genomics, transcriptomics, epigenomics, and metagenomics applications.

QIAGEN’s QIAseq kits have successfully processed over four million NGS samples, facilitating biomarker research, gene expression studies, viral epidemiology, and disease surveillance. The wide range of QIAseq kits covers DNA and RNA sequencing, multimodal sequencing, and epigenomics, providing reliable data on various sequencing instruments.

Complementing its sample processing technology, QIAGEN Digital Insight’s bioinformatics portfolio maximizes the potential of NGS on any sequencing platform. To maintain a leading position in the industry, QIAGEN actively fosters strategic partnerships to advance next-generation sequencing companion diagnostics. These tests offer valuable insights that can guide clinical decision-making and enhance patient outcomes by identifying individuals most likely to benefit from specific therapeutic products.

Learn more about QIAGEN’s QIAseq Normalizer kits for NGS at https://www.qiagen.com/applications/next-generation-sequencing/normalization.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2022, QIAGEN employed approximately 6,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Press Contact

Daniela Eltrop
Associate Director Public Relations
Germany: +49 2103 29 11676
Mobile: +49 152 01811676
daniela.eltrop@qiagen.com

Lisa Mannagottera
Associate Manager Public Relations
Germany: +49 2103 29 14181
Mobile: +49 152 01811381
lisa.mannagottera@qiagen.com

Dr. Thomas Theuringer
Senior Director Corporate Communications & Head Of External
Germany: +49 2103 29 11826
U.S.: +1 240 686 7425
The Netherlands: +31 773 55 66 66
thomas.theuringer@qiagen.com

IR Contacts

Phoebe Loh
Senior Director Investor Relations
+49 2103 29 11457
phoebe.loh@qiagen.com

Alexandra Koenig
Investor Relations Coordinator
+49 2103 29 11709
alexandra.koenig@qiagen.com

John Gilardi
Vice President
Head of Corporate Communications and Investor Relations
Germany +49 2103 29 11711
U.S. +1 240 686 2222
The Netherlands +31 773 55 66 66
john.gilardi@qiagen.com

SOURCE: QIAGEN